Author(s):
Mohammad Chand Jamali, Sameh Elsonbaty, Amina Toumi, Ali Jaber M Alqahtani, Mohammed Abdalhamied M. Abushohada, Ahmed Atef Ibrahim Belal, Hanan Mesfer Alyami, Maxime Merheb, Shashi Kumar, Rakesh Kumar Singh, Adham Elsonbaty
Email(s):
mjamali68@gmail.com , sameh.elsonbaty@lu.ac.ae , amina.eltomi@lu.ac.ae , ali.alqahtani@lu.ac.ae , dr.abdalhamied@gmu.ac.ae , belala@mcmaster.ca , malyami@pnu.edu.sa , maxime.merheb@dmu.ae , shashigmc@yahoo.co.in , rakeshsinghpu@gmail.com , adham.elsonbaty@gmail.com
DOI:
10.52711/0974-360X.2026.00336 
Address:
Mohammad Chand Jamali1*, Sameh Elsonbaty1, Amina Toumi1, Ali Jaber M Alqahtani1, Mohammed Abdalhamied M. Abushohada2, Ahmed Atef Ibrahim Belal3, Hanan Mesfer Alyami4, Maxime Merheb5, Shashi Kumar6, Rakesh Kumar Singh7, Adham Elsonbaty8
1College of Medical and Health Sciences, Liwa University, Abu Dhabi, United Arab Emirates.
2Thumbay College of Management and AI in Healthcare, Gulf Medical University, Ajman, United Arab Emirates.
3Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada.
4Department of Medical and Surgical Nursing, College of Nursing, Princess Nourah Bint Abdulrahman University, Riyadh 13412, Saudi Arabia.
5College of Health Sciences, Dubai Medical University, Dubai, United Arab Emirates.
6Director and HOD – Nephrology, Paras HMRI, Patna, India.
7Head, Centre for Nanoscience and Nanotechnology, Aryabhatta Knowledge University Patna, India.
8Medical Student, College of Medicine October 6 University, Egypt.
*Corr
Published In:
Volume - 19,
Issue - 5,
Year - 2026
ABSTRACT:
Introduction: A new era in drug discovery must start. Almost all pharmaceutical development methods use computer-based data and findings. This article highlights advanced simulation techniques for drug development. By 2040, the worldwide cancer burden will reach 30 million new cases, with the highest growth in low—and middle-income nations. By 2040, cancer diagnoses are predicted to grow by 55 percent, reaching 6.23 million in the Americas. Kinetic profiles of ligand binding mechanisms and drug-target affinities must be investigated. Methodology: A systematic literature review was conducted using multiple academic and scientific databases, including ResearchGate, ScienceDirect, CORE Library, Google, Web of Science, Google Scholar, and Scientific Digital Library Online (SciELO). The search covered publications from August 2009 to August 2024 to ensure the inclusion of foundational and recent studies. Result and Discussion: Plant-derived drugs include methyl transferase inhibitors, DNA damage inhibitors, HDAC inhibitors, and mitotic disruptors—the compounds' anticancer effectiveness and clinical trial development. MTAs are currently used in cancer detection since they target specific driver genes or diagnostics. This method is constrained by the high gene alterations in multiple driving genes in each tumor. Digital drug assignment (DDA) method that prioritizes potential.
Cite this article:
Mohammad Chand Jamali, Sameh Elsonbaty, Amina Toumi, Ali Jaber M Alqahtani, Mohammed Abdalhamied M. Abushohada, Ahmed Atef Ibrahim Belal, Hanan Mesfer Alyami, Maxime Merheb, Shashi Kumar, Rakesh Kumar Singh, Adham Elsonbaty. Computational Methodologies in the Discovery of Natural multi-target Drugs in Cancer Treatment. Research Journal Pharmacy and Technology. 2026;19(5):2343-8. doi: 10.52711/0974-360X.2026.00336
Cite(Electronic):
Mohammad Chand Jamali, Sameh Elsonbaty, Amina Toumi, Ali Jaber M Alqahtani, Mohammed Abdalhamied M. Abushohada, Ahmed Atef Ibrahim Belal, Hanan Mesfer Alyami, Maxime Merheb, Shashi Kumar, Rakesh Kumar Singh, Adham Elsonbaty. Computational Methodologies in the Discovery of Natural multi-target Drugs in Cancer Treatment. Research Journal Pharmacy and Technology. 2026;19(5):2343-8. doi: 10.52711/0974-360X.2026.00336 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-5-57
REFERENCES:
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12): 2893–917. doi:10.1002/ijc.25516.
2. Malnic B, Hirono J, Sato T, Buck LB. Combinatorial receptor codes for odors. Cell. 1999; 96(5): 713–23. doi:10.1016/s0092-8674(00)80581-4.
3. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016; 11(1): 39–51. doi:10.1016/j.jtho.2015.09.009.
4. World Health Organization (WHO). Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2019. Geneva: WHO; 2020.
5. Rahman Bhuiyan MK, Rahman DM, Kumar Das S, Shahidul Islam DSM, Mahmud DF, Mukit A, et al. Current aspects of non Hodgkin lymphoma (NHL) in Bangladesh: A mini review. Clin Med Health Res J [Internet]. 2023; 3(01): 312–6. Available from: https://doi.org/10.18535/cmhrj.v3i01.130
6. Geras KJ, Mann RM, Moy L. Artificial Intelligence for Mammography and Digital Breast Tomosynthesis: Current Concepts and Future Perspectives. Radiology. 2019; 293(2): 246–59. doi:10.1148/radiol.2019182627.
7. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021; 127(16): 3029–30. doi:10.1002/cncr.33587.
8. Hu L, Bell D, Antani S, Xue Z, Yu K, Horning MP, et al. An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening. J Natl Cancer Inst. 2019; 111(9): 923–32. doi:10.1093/jnci/djy225.
9. Tschandl P, Rinner C, Apalla Z, Argenziano G, Codella N, Halpern A, et al. Human-computer collaboration for skin cancer recognition. Nat Med. 2020; 26(8): 1229–34. doi:10.1038/s41591-020-0942-0.
10. Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017; 542(7639): 115–8. doi:10.1038/nature21056.
11. Liu Q, Lim SY, Soo RA, Park MK, Shin Y. A rapid MZI-IDA sensor system for EGFR mutation testing in non-small cell lung cancer (NSCLC). Biosens Bioelectron. 2015; 74: 865–71. doi:10.1016/j.bios.2015.07.055.
12. Bayley JP, Devilee P. Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Curr Opin Genet Dev. 2010;20(3):324–9. doi:10.1016/j.gde.2010.02.008.
13. Shah U, Shah R, Acharya S, Acharya N. Novel anticancer agents from plant sources. Chin J Nat Med. 2013; 11(1): 16–23. doi:10.1016/s1875-5364(13)60002-3.
14. Phillipson JD. Medicinal plants. J Bio Educ. 1997; 31(2): 109–15.
15. Khazir J, Mir BA, Pilcher L, Riley DL. Role of plants in anticancer drug discovery. Phytochem Lett. 2014; 7: 173–81. doi:10.1016/j.phytol.2013.11.010.
16. Kumar R, Saha P, Nyarko RO, Lokare P, Boateng ADE, Kahwa I, et al. Effect of covid-19 in management of lung cancer disease: A review. Asian J Pharm Res Dev. 2022; 10(3): 58–64. doi:10.22270/ajprd.v10i3.1131.
17. Solowey E, Lichtenstein M, Sallon S, Paavilainen H, Solowey E, Lorberboum-Galski H. Evaluating medicinal plants for anticancer activity. Sci World J. 2014; 2014: 721402. doi:10.1155/2014/721402.
18. Afrin S, Pillai HPJS, Emmanuel ESC, Viktor P, Al Hafiz M, Aboqade Al-Aouadi RF, et al. A systematic review of bioinformatics’ influence on drug developments. Res J Pharm Technol. 2024; 17(6): 6158–64. Available from: https://doi.org/10.52711/0974-360x.2024.00934
19. Mahedi RA, Iqbal H, Azmee R, Azmee M, Jakir F, Nishan MA, et al. Current trends and future prospects of artificial intelligence in transforming radiology. J Curr Health Sci. 2024; 4(2): 95–104. Available from: https://doi.org/10.47679/jchs.202487
20. Bhatnagar P, Pant AB, Shukla Y, Chaudhari B, Kumar P, Gupta KC. Bromelain nanoparticles protect against 7,12-dimethylbenz[a]anthracene induced skin carcinogenesis in mouse model. Eur J Pharm Biopharm. 2015; 91: 35–46. doi:10.1016/j.ejpb.2015.01.015.
21. Zschocke S, Rabe T, Taylor JL, Jager AK, van Staden J. Plant part substitution--a way to conserve endangered medicinal plants? J Ethnopharmacol. 2000; 71(1-2): 281–92. doi:10.1016/s0378-8741(00)00186-0.
22. Stagos D, Amoutzias GD, Matakos A, Spyrou A, Tsatsakis AM, Kouretas D. Chemoprevention of liver cancer by plant polyphenols. Food Chem Toxicol. 2012; 50(6): 2155–70. doi:10.1016/j.fct.2012.04.002.
23. Zajicek G. Cancer and metaphysics. Med Hypotheses. 2001; 57(2): 243–8. doi:10.1054/mehy.2001.1348.
24. Starwyn D. The Psycho-Emotional Roots of Cancer. Acupunct Today. 2012;13.
25. Kearney KG, Hicks RE. Self-compassion and breast cancer in 23 cancer respondents: Is the way you relate to yourself a factor in disease onset and progress? Psychology (Irvine). 2017; 8(1): 14–26. doi:10.4236/psych.2017.81002.
26. Rahnama M, Khoshknab MF, Maddah SS, Ahmadi F. Iranian cancer patients' perception of spirituality: a qualitative content analysis study. BMC Nurs. 2012; 11: 19. doi:10.1186/1472-6955-11-19.
27. Chauhan A, Semwal DK, Mishra SP, Semwal RB. Ayurvedic concept of Shatkriyakala: a traditional knowledge of cancer pathogenesis and therapy. J Integr Med. 2017; 15(2): 88–94. doi:10.1016/S2095-4964(17)60311-X.
28. Haber DA, Settleman J. Cancer: drivers and passengers. Nature. 2007; 446(7132): 145–6. doi:10.1038/446145a.
29. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab [Internet]. 2008; 7(1): 11–20. Available from: http://doi.org/10.1016/j.cmet.2007.10.002
30. McFarland CD, Mirny LA, Korolev KS. Tug-of-war between driver and passenger mutations in cancer and other adaptive processes. Proc Natl Acad Sci U S A [Internet]. 2014; 111(42): 15138–43. Available from: http://doi.org/10.1073/pnas.1404341111
31. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009; 458(7239): 719–24. doi:10.1038/nature07943.
32. Salichos L, Meyerson W, Warrell J, Gerstein M. Estimating growth patterns and driver effects in tumor evolution from individual samples. Nat Commun [Internet]. 2020; 11(1): 732. Available from: http://dx.doi.org/10.1038/s41467-020-14407-9
33. Kumar S, Gerstein M. Cancer genomics: Less is more in the hunt for driver mutations. Nature. 2017; 547(7661): 40–1. doi:10.1038/nature23085.
34. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012; 14: 1–16. doi:10.1146/annurev-bioeng-071811-150124.
35. Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc Res. 1986; 31(3): 288–305. doi:10.1016/0026-2862(86)90018-x.
36. Kim EM, Jeong HJ. Current Status and Future Direction of Nanomedicine: Focus on Advanced Biological and Medical Applications. Nucl Med Mol Imaging. 2017; 51(2): 106–17. doi:10.1007/s13139-016-0435-8.
37. Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2019; 47(D1): D941–7. doi:10.1093/nar/gky1015.
38. Patidar A, Shivhare SC, Ateneriya U, Choudhary S. A Comprehensive Review on Breast Cancer. Asian J Nurs Educ Res. 2012; 2(1): 28–32.
39. Iranmanesh S, Shamsi A. The Relationship between Type of Cancer and Parent's Psychosocial Risks. Asian J Nurs Educ Res. 2014; 4(4): 495–501.
40. Raju CP, Babu GR, Sowjanya M, Ramayyappa M. Evaluation of Cancer Bio-markers through Hyphenated Analytical Techniques. Asian J Pharm Anal. 2021; 11(3): 235–42.
41. Honale VS, Muneshwar SD, Thipe SS, Sawale AV. Formulation and Evaluation of Herbal Anticancer Chewing Gum. Asian J Pharm Anal. 2023; 13(4): 278–84.
42. Kumbhar S, Salunkhe V, Magdum C. Targeted Drug Delivery: A Backbone for Cancer Therapy. Asian J Pharm Res. 2013; 3(1): 40–6.